The Management of Locally Radiorecurrent Prostate Cancer

In the era of PSMA PET and the increased availability of SBRT, radiation oncologists must remain current on state-of-the art techniques to reduce toxicity and optimize cure. This webinar reviews methods that physicians can integrate into their clinics to offer their patients the highest level of care. It also covers aggressive therapy options for the management of patients with locally radiorecurrent prostate cancer.  

Target Audience

This activity is designed to meet the interests of radiation oncologists, physicists, radiation dosimetrists, radiation therapists and residents. 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Describe methods to optimize cure in those with localized or oligometastatic prostate cancer. 
  • Discuss techniques to mitigate toxicity in the treatment of prostate cancer. 
  • Review treatment options for locally radiorecurrent prostate cancer. 
  • Consider the use of salvage therapy for radiorecurrent prostate cancer. 
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
08/19/2024
Course expires: 
10/12/2026
Cost:
$0.00
Part of: 
Definitive and Salvage Radiation Therapy for Prostate Cancer
Rating: 
0
  • Abhishek Solanki, MD, MS, is employed by Loyola University Medical Center and the Edward Hines Jr. VA Hospital. Dr. Solanki receives grant/research funding from the US Department of Veteran's Affairs. Dr. Solanki serves as an Executive Committee Member with the American College of Radiology.  
  • Shauna McVorran, MD, MHSA, is employed by Geisel School of Medicine at Dartmouth and the Dartmouth Cancer Center.
  • Bhanu Prasad Venkatesulu, MD, MBBS, is employed by University of Pittsburgh Medical Center. Dr. Venkatesulu receives grant/research funding from Thomas Gore pancreatic cancer and Gateway to cancer research. Dr. Venkatesulu owns stock in ImmunityBio and Spectrum Pharmaceuticals. Dr. Venkatesulu serves as an Education committee member of ASTRO, a task force mentee with ICRP, an Adhoc member of RadOnc questions, and is a consultant on guidelines with the American Radium Society. 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.